Introduction
Molecular targeted cancer therapies are the biggest and fastest
growing class of cancer drugs in terms of sales. As growth of
revenues from cytotoxic therapies and antihormonal therapies has
slowed and many key brands in these classes face imminent patent
expiries, it is unsurprising that the major oncology companies
have shifted their focus towards the molecular targeted cancer
therapies market.
Scope
- Forecast sales of every marketed molecular targeted cancer
therapy in each of the seven major markets over the period 2008
to 2018
- Analysis and segmentation of the market at various levels
including drug class, country, brand and company
- Comprehensive brand profiles and analysis for the key brands,
including approval dates, patent expiries and all key events
likely to impact sales
- Snapshot of the molecular targeted cancer therapies market in
the rest of the world
Highlights
Total sales of marketed molecular targeted cancer therapies in
the seven major pharmaceutical markets will grow at a CAGR of
9.8% from $17.5 billion in 2008 to $44.7 billion in 2018.
Drivers of growth will include the continuing adoption of
molecular targeted cancer therapies in currently approved
indications and approvals in new indications.
Avastin (bevacizumab;
Roche/Chugai) was the top-selling molecular targeted cancer
therapy brand in 2008, and will remain the leading brand in
2018. Avastin will achieve this growth through indication
expansion across a number of new tumor types and increasing
uptake in new territories.
With a dominant presence in three of the four highest incidence
solid tumors and the highest incidence hematological malignancy,
Roche has established a stranglehold over the molecular targeted
cancer therapies market. This will continue through to 2018,
driven mainly by the strong performance of the company's
monoclonal antibody franchise.
Reasons to Purchase
- Quantify the performance of each of the marketed molecular
targeted cancer therapies in the seven major markets over the
period 2008 to 2018
- Assess the changing key opportunities and threats both for
currently marketed and pipeline targeted therapy cancer brands
- Identify the leading brands in this market over the next 10
years and understand the key factors driving their success
